Table 2.

Characteristics of Human and Pig Populations during Each Phase of the Cysticercosis Elimination Demonstration Program.^*

Characteristic	Phase 1						Phase 2				Phase 3
	Mass Treatment	Minimal Mass Treatment	Strategic Treatment	Mass Screening	Prevention Education	Pig Replacement	Mass Treatment with Vaccine	Mass Treatment without Vaccine	Mass Screening with Vaccine	Mass Screening without Vaccine	Mass Treatment with Vaccine
Villages — no.	7	7	7	7	8	6	3	6	3	5	107
Humans — no.	2651	2127	2285	1660	1554	476	3418	2323	1756	2883	81,170
Male sex — %	51.3	52.6	53.8	51.8	53.0	52.7	51.1	54.6	50.2	51.1	51.4
Median age (IQR) — yr	27 (13–44)	26 (13–42)	25 (13–44)	27 (13–44)	26 (13–45)	24 (10–43)	26 (14–43)	27 (15–46)	28 (14–44)	28 (15–48)	25 (12–42)
Pigs — no.	3557	2909	3478	3441	3253	464	3255	3485	2874	3874	55,638
Male sex — %	42.7	45.7	44.7	46.2	46.4	42.2	44.9	43.4	42.3	43.9	NA
Median age (IQR) — mo	6 (2–12)	6 (3–12)	6 (3–12)	6 (3–12)	5 (2–12)	7 (3–18)	6 (3–10)	6 (3–10)	6 (3–10)	6 (3–10)	NA
Baseline prevalence of cysticercosis — %†	44.6	34.7	45.7	41.0	50.2	42.9	24.5	47.8	47.3	28.1	NA

^*The groups differed significantly only with regard to antibody prevalence. NA denotes not assessed.

^†Prevalence was assessed by enzyme-linked immunoelectrotransfer blot antibody testing.